Shots:
Viatris has entered into a definitive agreement to acquire Pacira BioSciences, advancing its innovative medicines strategy and becoming a leader in non-opioid pain therapies
As per the deal, Viatris will acquire Pacira for $36.5/share in cash, representing an aggregate equity value of $1.65B, with remaining shares acquired later via a second-step merger; closing is…
